Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nebido Will Emerge As Hypogonadism Treatment Leader, Indevus Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Indevus expects Nebido to acquire the majority of the injectable testosterone hypogonadism treatment market when it launches in the U.S., the company said in an Aug. 9 earnings call

You may also be interested in...

Indevus To Market Nebido In The U.S. Upon Approval

Indevus expects to file an NDA for the injectable testosterone therapy, licensed from Schering AG, for the treatment of hypogonadism in the second half of 2006.

Esprit Pharma Plans November Launch Of Proquin XR Following Licensing Deal

Esprit’s 100 sales reps will initially target marketing efforts to 8,000 urologist offices, with eventual movement to ob/gyn and family practitioners.

Savient Delays 10-Q Filing Due To Oxandrin Return Reserve Errors

The firm will restate first quarter and 2004 year-end results due to less-than-expected returns of the anabolic agent.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts